ZA201406225B - Thiadiazolidinediones as gsk-3 inhibitors - Google Patents
Thiadiazolidinediones as gsk-3 inhibitorsInfo
- Publication number
- ZA201406225B ZA201406225B ZA2014/06225A ZA201406225A ZA201406225B ZA 201406225 B ZA201406225 B ZA 201406225B ZA 2014/06225 A ZA2014/06225 A ZA 2014/06225A ZA 201406225 A ZA201406225 A ZA 201406225A ZA 201406225 B ZA201406225 B ZA 201406225B
- Authority
- ZA
- South Africa
- Prior art keywords
- thiadiazolidinediones
- gsk
- inhibitors
- Prior art date
Links
- 101150090422 gsk-3 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- PZWGPRQVKJVQSE-UHFFFAOYSA-N thiadiazolidine-4,5-dione Chemical class O=C1NNSC1=O PZWGPRQVKJVQSE-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382066 | 2012-02-24 | ||
| PCT/EP2013/053554 WO2013124413A1 (en) | 2012-02-24 | 2013-02-22 | Thiadiazolidinediones as gsk-3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201406225B true ZA201406225B (en) | 2016-05-25 |
Family
ID=47747639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/06225A ZA201406225B (en) | 2012-02-24 | 2014-08-25 | Thiadiazolidinediones as gsk-3 inhibitors |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9371299B2 (https=) |
| EP (1) | EP2838888B1 (https=) |
| JP (2) | JP6073377B2 (https=) |
| AU (2) | AU2013224041B2 (https=) |
| CA (1) | CA2865351C (https=) |
| CY (1) | CY1119231T1 (https=) |
| DK (1) | DK2838888T3 (https=) |
| ES (1) | ES2632428T3 (https=) |
| HR (1) | HRP20170964T1 (https=) |
| HU (1) | HUE035089T2 (https=) |
| IN (1) | IN2014DN07885A (https=) |
| LT (1) | LT2838888T (https=) |
| NZ (1) | NZ630615A (https=) |
| PL (1) | PL2838888T3 (https=) |
| PT (1) | PT2838888T (https=) |
| SI (1) | SI2838888T1 (https=) |
| WO (1) | WO2013124413A1 (https=) |
| ZA (1) | ZA201406225B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6073377B2 (ja) | 2012-02-24 | 2017-02-01 | エーエスディー セラピューティクス パートナーズ エルエルシーＡｓｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｐａｒｔｎｅｒｓ Ｌｌｃ | Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン |
| PL2970890T3 (pl) | 2013-03-14 | 2020-11-16 | The Brigham And Women's Hospital, Inc. | Kompozycje i sposoby ekspansji i hodowli nabłonkowych komórek macierzystych |
| MX388409B (es) * | 2014-06-12 | 2025-03-19 | Cedars Sinai Medical Center | Composiciones y metodos para tratar canceres. |
| EP3189134A1 (en) | 2014-09-03 | 2017-07-12 | The Brigham and Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
| US11021687B2 (en) | 2016-01-08 | 2021-06-01 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| EP3562827A1 (en) | 2016-12-30 | 2019-11-06 | Frequency Therapeutics, Inc. | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
| US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
| JP2021533788A (ja) | 2018-08-17 | 2021-12-09 | フリークエンシー セラピューティクス インコーポレイテッド | Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法 |
| CN113168150B (zh) * | 2018-10-16 | 2024-05-10 | 意大利技术联盟有限责任公司 | 具有被处理幅材的评估系统的卷绕机和方法 |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| CA3207901A1 (en) * | 2021-02-11 | 2022-08-18 | Jason Roberts | Compositions and methods for treating arrhythmogenic cardiomyopathy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2166328B1 (es) * | 2000-05-11 | 2003-09-16 | Consejo Superior Investigacion | Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos |
| AU783615B2 (en) * | 2000-05-11 | 2005-11-17 | Consejo Superior De Investigaciones Cientificas | Heterocyclic inhibitors of glycogen synthase kinase GSK-3 |
| EP1586318A1 (en) | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiadiazolidinones as GSK-3 inhibitors |
| KR100837785B1 (ko) * | 2007-01-17 | 2008-06-13 | 한국화학연구원 | 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물 |
| JP6073377B2 (ja) | 2012-02-24 | 2017-02-01 | エーエスディー セラピューティクス パートナーズ エルエルシーＡｓｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｐａｒｔｎｅｒｓ Ｌｌｃ | Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン |
-
2013
- 2013-02-22 JP JP2014558118A patent/JP6073377B2/ja active Active
- 2013-02-22 DK DK13705492.0T patent/DK2838888T3/en active
- 2013-02-22 WO PCT/EP2013/053554 patent/WO2013124413A1/en not_active Ceased
- 2013-02-22 SI SI201330704T patent/SI2838888T1/sl unknown
- 2013-02-22 CA CA2865351A patent/CA2865351C/en active Active
- 2013-02-22 LT LTEP13705492.0T patent/LT2838888T/lt unknown
- 2013-02-22 HU HUE13705492A patent/HUE035089T2/hu unknown
- 2013-02-22 PL PL13705492T patent/PL2838888T3/pl unknown
- 2013-02-22 ES ES13705492.0T patent/ES2632428T3/es active Active
- 2013-02-22 PT PT137054920T patent/PT2838888T/pt unknown
- 2013-02-22 EP EP13705492.0A patent/EP2838888B1/en active Active
- 2013-02-22 IN IN7885DEN2014 patent/IN2014DN07885A/en unknown
- 2013-02-22 AU AU2013224041A patent/AU2013224041B2/en active Active
- 2013-02-22 HR HRP20170964TT patent/HRP20170964T1/hr unknown
- 2013-02-22 NZ NZ630615A patent/NZ630615A/en unknown
- 2013-02-22 US US14/380,623 patent/US9371299B2/en active Active
-
2014
- 2014-08-25 ZA ZA2014/06225A patent/ZA201406225B/en unknown
-
2016
- 2016-05-16 US US15/155,437 patent/US9469618B2/en active Active
-
2017
- 2017-01-04 JP JP2017000211A patent/JP6518270B2/ja active Active
- 2017-07-12 CY CY20171100737T patent/CY1119231T1/el unknown
- 2017-10-20 AU AU2017248556A patent/AU2017248556B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2838888T3 (en) | 2017-07-17 |
| CA2865351C (en) | 2019-08-20 |
| JP2017081974A (ja) | 2017-05-18 |
| AU2013224041B2 (en) | 2017-08-24 |
| SI2838888T1 (sl) | 2017-09-29 |
| AU2013224041A1 (en) | 2014-09-25 |
| WO2013124413A1 (en) | 2013-08-29 |
| JP6518270B2 (ja) | 2019-05-22 |
| CY1119231T1 (el) | 2018-02-14 |
| JP6073377B2 (ja) | 2017-02-01 |
| AU2017248556B2 (en) | 2018-08-09 |
| US20150038538A1 (en) | 2015-02-05 |
| ES2632428T3 (es) | 2017-09-13 |
| JP2015508092A (ja) | 2015-03-16 |
| EP2838888A1 (en) | 2015-02-25 |
| HUE035089T2 (hu) | 2018-05-02 |
| IN2014DN07885A (https=) | 2015-04-24 |
| AU2017248556A1 (en) | 2017-11-09 |
| US9371299B2 (en) | 2016-06-21 |
| HK1207366A1 (en) | 2016-01-29 |
| LT2838888T (lt) | 2017-08-10 |
| NZ630615A (en) | 2015-09-25 |
| PL2838888T3 (pl) | 2017-12-29 |
| EP2838888B1 (en) | 2017-04-12 |
| HRP20170964T1 (hr) | 2017-10-06 |
| PT2838888T (pt) | 2017-07-18 |
| US20160257660A1 (en) | 2016-09-08 |
| US9469618B2 (en) | 2016-10-18 |
| CA2865351A1 (en) | 2013-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201501009B (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| IL239435A0 (en) | Ototaxin inhibitors | |
| ZA201503041B (en) | Gdf-8 inhibitors | |
| ZA201407694B (en) | Substituted pyrrolidine-2-carboxamides | |
| LT2892889T (lt) | Inhibitoriaus junginiai | |
| PT2920149T (pt) | Compostos de 3-aminocicloalquil como inibidores de ror-gama-t e utilizações dos mesmos | |
| SG11201404344XA (en) | Substituted pyrrolidine-2-carboxamides | |
| ZA201406225B (en) | Thiadiazolidinediones as gsk-3 inhibitors | |
| SG11201501173SA (en) | PI3Kδ INHIBITOR | |
| IL245442A0 (en) | gsk–3 inhibitors | |
| SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
| IL239153A0 (en) | Substitute pyridopyrazine as an inhibitor | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| EP2934541A4 (en) | NORIBOGAINE SUBSTITUTE | |
| PL2912021T3 (pl) | Inhibitory agrekanazy | |
| EP2847186A4 (en) | SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER | |
| EP2885291A4 (en) | INHIBITORS OF VEGFR3 | |
| EP2885292A4 (en) | VEGFR3 INHIBITORS | |
| GB201211019D0 (en) | Inhibitor compounds | |
| ZA201504305B (en) | Autotaxin inhibitors | |
| GB201216008D0 (en) | Novel use of GSK-3 inhibitors | |
| AP2015008541A0 (en) | Autotaxin inhibitors |